8legs: U.s. securities and exchange commission

Your Followed Topics

#1 out of 5

Interactive Strength increases its maximum aggregate offering price to $2,608,000 under the Sales Agreement.
The company filed a prospectus supplement for the new offering amount.
Interactive Strength had previously sold shares totaling $1,646,532 in the last 12 months.
Shares are issued under an effective shelf registration statement.
The update aligns with ongoing offering strategy and regulatory filings.
The reference mentions the context of the typical 8-K filing and SEC disclosures.
TradingView provides latest news and analysis on US stocks including Interactive Strength.
The information is presented as an AI-powered summary requiring verification.
The article cites an increase in offering price alongside previous activity and shelf registration.

Vote 0

#2 out of 5

Silbert increases lobbying spending in Washington as DCG faces several lawsuits and fraud allegations.
DCG aims to take Grayscale Investments public in a potential $33 billion IPO, per sources.
Investors and officials remain skeptical about spending amid ongoing fraud lawsuits and Genesis-related claims.
DCG reportedly paid $38.5 million to the SEC in January 2025 for investor misrepresentation.
Grayscale's IPO prospects are cited as a possible tool to fund settlements and litigation.
Supporters argue DCG pursues lobbying to educate lawmakers on policy issues at stake.
Some creditors accuse Silbert and insiders of shifting funds before Genesis’ 2023 bankruptcy.
Former advisor Larry Summers reportedly left Harvard amid Epstein ties revelations.
Barclays and Bloomberg are cited as sources noting Silbert’s lobbying growth.
DCG’s public stance emphasizes bipartisan and transparent lobbying activity.

Vote 0

#3 out of 5

ADM agrees to a $40 million civil penalty to settle SEC charges over intersegment accounting issues tied to its Nutrition unit, ending a long-running inquiry.
The DOJ closed its criminal probe without charges as part of the settlement, aligning with the SEC resolution.
Investigations spanned years, prompting multiple restatements of financial results and shareholder litigation.
ADM says it enhanced internal controls and amended policies as part of remedial measures cited by the SEC.
Former executives Vince Macciocchi and Ray Young were named in SEC action related to the case.
ADM’s CEO Juan Luciano asserted the company is pleased to put the matter behind them as part of the settlement.
The Nutrition unit, created in 2018, was central to the accounting scrutiny and restatements.
ADM cooperated with regulators, providing an internal review and analyses from an outside accounting expert.
The settlement focuses on intersegment transactions and reinforces ongoing reforms to internal controls at ADM.
Trading and market reaction showed ADM shares edging higher after-hours on the settlement news.

Vote 1

#4 out of 5

Vyome reports VT-1953 valued at $455 million after Phase 2, with potential to hit $1 billion post-Phase 3.
Estimated peak U.S. sales for VT-1953 are about $600 million annually.
The U.S. MFW treatment market is about $2.2 billion in total addressable market.
Vyome aims for VT-1953 to be the first FDA-approved therapy for MFW symptoms.
Destum Partners conducted the independent market analysis for Vyome.
The summary notes the information is AI-generated and may contain inaccuracies.
The filing cited is Vyome's 8-K dated January 28, 2026.
The report stresses the information is based on SEC documents and should be verified.
The release positions VT-1953 within a broader $2.2 billion MFW market in the U.S.

Vote 0

#5 out of 5

The SEC filed a complaint on December 22, 2025, alleging market manipulation and insider trading involving Olema and Opiant.
The action describes a pump-and-dump scheme using fake sources to inflate Olema’s stock price.
Impersonation of physicians and fake domains were used to obtain MNPI about Olema’s trial results.
Defendants allegedly published falsified study results to pump Olema’s stock before a trading halt.
Separately, insiders allegedly misused MNPI about acquisitions to profit from trading.
Opiant trades were boosted by alleged MNPI and a falsified acquisition rumor.
SEC notes heightened vigilance is needed as these companies pursue regulatory approval.
The action cites the risk to directors, institutional investors, and MNPI safeguards.
Directors should ensure internal safeguards to reduce improper trading risk.

Vote 0

Unlimited Access

Personalized Feed

Full Experience

By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.

Create an account and enjoy content that interests you with your personalized feed

Unlimited Access

Personalized Feed

Full Experience

By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.